Braveheart Bio Inc. (BRVE)
NASDAQ: BRVEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BRVE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.67B
- EPS (TTM)
- -$6.59
- Dividend yield
- None
- 52-week range
- 16.70 – 32.00
- Day range
- 18.83 – 21.11
- Volume / Avg
- 866.73K / 491.27K
- Beta
- —
- Shares outstanding
- 82.07M
- Next earnings
- Dec 8, 2026
52-week range
BRVE stock today
Shares of Braveheart Bio (BRVE) finished higher on Nov 20 at $20.39, a gain of 5.81% or $1.12 per share, versus the S&P 500's 3.70% decline. Shares are 36.3% below their 52-week high of $32.00, set on Aug 7, 2026 and 22.1% above the 52-week low of $16.70, in the middle of the past year's range. Braveheart Bio has posted a net loss over the last twelve months (EPS of -$6.59), so its P/E ratio is not meaningful.
The company is scheduled to report Sep/2026 results on Dec 8; analysts expect EPS of -$0.91.
Summary generated from market data by MetaCap's automated system. Methodology
About Braveheart Bio
Company profileBraveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Travis Murdoch B.S., M.D., M.Sc.
- Headquarters
- San Francisco, CA
- Employees
- 49
- IPO year
- 2026
- Website
- braveheart.bio
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$45.50+123.15%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Dec 8, 2026
- EPS estimate
- $-0.91
- Last reported (Sep/2026)
- Dec 8, 2026
- EPS actual vs est.
- $-0.51 vs $-0.91
- Surprise
- +43.96%
BRVE news
All BRVE news- Braveheart Bio, Inc. GAAP EPS of -$0.51 misses by $0.07Seeking Alpha
- Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in LondonGlobeNewswire
- Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026GlobeNewswire
- Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026GlobeNewswire
- Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026GlobeNewswire
Braveheart Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RAREUltragenyx Pharmaceutical Inc. | 16.48 | -4.30% | $1.68B | vs BRVE |
| AGIOAgios Pharmaceuticals Inc. | 27.60 | -4.03% | $1.65B | vs BRVE |
| KRSAKorsana Biosciences Inc. | 37.56 | +5.95% | $1.71B | vs BRVE |
| SDGRSchrodinger Inc. | 22.93 | -12.95% | $1.72B | vs BRVE |
| ZBIOZenas BioPharma Inc. | 23.85 | -4.75% | $1.62B | vs BRVE |
| TRAXFirst Tracks Biotherapeutics Inc. | 41.64 | -6.34% | $1.75B | vs BRVE |
| STOKStoke Therapeutics Inc. | 26.81 | -0.45% | $1.75B | vs BRVE |
| ETONEton Pharmaceuticals Inc. | 60.85 | -0.83% | $1.76B | vs BRVE |
Indexes, lists and sector
Braveheart Bio stock FAQ
What is Braveheart Bio's stock price today?
BRVE last traded at $20.39 as of Nov 20, 4:00 PM EST, up 5.81% on the day. Prices are delayed at least 15 minutes.
When is Braveheart Bio's next earnings date?
Braveheart Bio is expected to report earnings on Tuesday, December 8, 2026. Analysts expect EPS of $-0.91.
Who is Braveheart Bio's CEO?
Dr. Travis Murdoch B.S., M.D., M.Sc. is the chief executive officer of Braveheart Bio Inc., which has about 49 employees.
What is the BRVE 52-week high?
The 52-week high for BRVE is $32.00 and the 52-week low is $16.70. The stock is currently 36.3% below its high.